Összes fotó(1)
Fontos dokumentumok
1359404
USP
Levetiracetam
United States Pharmacopeia (USP) Reference Standard
Szinonimák:
(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-Oxopyrrolidin-1-yl)butyramide
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
Tapasztalati képlet (Hill-képlet):
C8H14N2O2
CAS-szám:
Molekulatömeg:
170.21
MDL-szám:
UNSPSC kód:
41116107
PubChem Substance ID:
NACRES:
NA.24
Javasolt termékek
grade
pharmaceutical primary standard
API-család
levetiracetam
gyártó/kereskedő neve
USP
alkalmazás(ok)
pharmaceutical (small molecule)
Formátum
neat
SMILES string
CC[C@H](N1CCCC1=O)C(N)=O
InChI
1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
Nemzetközi kémiai azonosító kulcs
HPHUVLMMVZITSG-LURJTMIESA-N
Géninformáció
human ... CACNA1B(774) , SV2A(9900)
Looking for similar products? Látogasson el ide Útmutató a termékösszehasonlításhoz
Általános leírás
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Alkalmazás
Levetiracetam USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Biokémiai/fiziológiai hatások
Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
Analízis megjegyzés
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Egyéb megjegyzések
Sales restrictions may apply.
kapcsolódó termék
Product No.
Leírás
Árazás
Tárolási osztály kódja
11 - Combustible Solids
WGK
WGK 3
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Válasszon a legfrissebb verziók közül:
Analitikai tanúsítványok (COA)
Lot/Batch Number
Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.
Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Az ügyfelek ezeket is megtekintették
Justin B Usery et al.
Journal of neuro-oncology, 99(2), 251-260 (2010-02-11)
To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection. Brain tumor patients undergoing neurosurgery with >or=1 seizure within the preceding month prior to surgery were enrolled to receive intravenous
Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
Rafal M Kaminski et al.
Epilepsia, 50(3), 387-397 (2008-07-17)
Levetiracetam (Keppra) is an antiepileptic drug (AED) characterized by a novel mechanism of action, unique profile of activity in seizure models, and broad-spectrum clinical efficacy. The present report critically reviews several preclinical studies focused on combination therapy with levetiracetam and
J Rösche et al.
Fortschritte der Neurologie-Psychiatrie, 81(1), 21-27 (2012-08-15)
Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by
Katherine A Lyseng-Williamson
Drugs, 71(4), 489-514 (2011-03-15)
Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with
Muhammad U Farooq et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 66(6), 541-561 (2009-03-07)
The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed. Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással